Third time unlucky as Luitpold receives another US complete response for Ferinject
This article was originally published in Scrip
Executive Summary
Luitpold Pharmaceuticals has yet again received a complete response letter from the US FDA for its new drug application (NDA) for the intravenous iron preparation, Ferinject (ferric carboxymaltose; brand name Injectafer outside the US) for the treatment of iron deficiency anemia, its partner Galenica said.